NCT05551624

Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine

Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine in Patients With Primary Immune Thrombocytopenia Resistant to Steroid Treatment or in Relapse: An Exploratory Clinical Trial

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Hospital Civil de Guadalajara · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the ability of Atorvastatin and N-acetyl cysteine to elevate the blood (serum) platelet count in patients with Immune Thrombocytopenia as a mean of a new treatment.

Detailed description

Evaluate the efficacy in the elevation of platelet count of the combination of atorvastatin and N-acetyl cysteine in patients with immune thrombocytopenia resistant to steroid therapy or with relapse after treatment, a prospective, proof of concept clinical trial.

Conditions

• Primary Immune Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet	Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours

Timeline

• Start date: 2018-07-04
• Primary completion: 2019-12-11
• Completion: 2020-01-23
• First posted: 2022-09-22
• Last updated: 2022-09-22

Locations

1 site across 1 country: Mexico